Targeting CTLA-4 in cancer : Is it the ideal companion for PD-1 blockade immunotherapy combinations?
© 2020 UICC..
Immunotherapy approaches boosting spontaneous and durable antitumor immune responses through immune checkpoint blockade are revolutionizing treatment and patient outcomes in solid tumors and hematological malignancies. Among the various inhibitory molecules employed by the immune system to regulate the adaptive immune responses, cytotoxic T lymphocyte antigen-4 (CTLA-4) is the first successfully targeted immune checkpoint molecule in the clinic, giving rise to significant but selective benefit either when targeted alone or in combination with anti-programmed cell death protein-1 (PD-1) antibodies (Abs). However, the use of anti-CTLA-4 Abs was associated with the incidence of autoimmune-like adverse events (AEs), which were particularly frequent and severe with the use of combinational strategies. Nevertheless, the higher incidence of AEs is associated with an improved clinical benefit indicating treatment response. A prompt recognition of AEs followed by early and adequate treatment with immunosuppressive agents allows the management of these potentially serious AEs. This narrative review aims to summarize CTLA-4 biology, the rationale for the use as a companion for anti-PD-1 Abs in humans with results from the most relevant Phase III clinical trials including anti-CTLA-4 Abs in combination with anti-PD-1 Abs in solid tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
International journal of cancer - 149(2021), 1 vom: 01. Juli, Seite 31-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Silva, Pushpamali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.09.2021 Date Revised 06.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.33415 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318191660 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318191660 | ||
| 003 | DE-627 | ||
| 005 | 20231225164835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.33415 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318191660 | ||
| 035 | |a (NLM)33252786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Silva, Pushpamali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting CTLA-4 in cancer |b Is it the ideal companion for PD-1 blockade immunotherapy combinations? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2021 | ||
| 500 | |a Date Revised 06.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 UICC. | ||
| 520 | |a Immunotherapy approaches boosting spontaneous and durable antitumor immune responses through immune checkpoint blockade are revolutionizing treatment and patient outcomes in solid tumors and hematological malignancies. Among the various inhibitory molecules employed by the immune system to regulate the adaptive immune responses, cytotoxic T lymphocyte antigen-4 (CTLA-4) is the first successfully targeted immune checkpoint molecule in the clinic, giving rise to significant but selective benefit either when targeted alone or in combination with anti-programmed cell death protein-1 (PD-1) antibodies (Abs). However, the use of anti-CTLA-4 Abs was associated with the incidence of autoimmune-like adverse events (AEs), which were particularly frequent and severe with the use of combinational strategies. Nevertheless, the higher incidence of AEs is associated with an improved clinical benefit indicating treatment response. A prompt recognition of AEs followed by early and adequate treatment with immunosuppressive agents allows the management of these potentially serious AEs. This narrative review aims to summarize CTLA-4 biology, the rationale for the use as a companion for anti-PD-1 Abs in humans with results from the most relevant Phase III clinical trials including anti-CTLA-4 Abs in combination with anti-PD-1 Abs in solid tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CTLA-4 | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a immune checkpoint blockade | |
| 650 | 4 | |a immune checkpoints | |
| 650 | 4 | |a immune-related adverse events | |
| 650 | 4 | |a immunotherapy | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a CTLA4 protein, human |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Aiello, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Gu-Trantien, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a Migliori, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Willard-Gallo, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Solinas, Cinzia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 149(2021), 1 vom: 01. Juli, Seite 31-41 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2021 |g number:1 |g day:01 |g month:07 |g pages:31-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.33415 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2021 |e 1 |b 01 |c 07 |h 31-41 | ||